Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy

  • Miwa, Takashi (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Kanda, Mitsuro (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Tanaka, Chie (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Kobayashi, Daisuke (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Hayashi, Masamichi (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Yamada, Suguru (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Nakayama, Goro (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Koike, Masahiko (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine) ;
  • Kodera, Yasuhiro (Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine)
  • Received : 2019.02.02
  • Accepted : 2019.04.09
  • Published : 2019.06.28
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Due to adverse events, dose reduction or withdrawal of adjuvant chemotherapy is required for some patients. To identify the predictive factors for tolerability to postoperative adjuvant S-1 monotherapy in gastric cancer (GC) patients, we evaluated the predictive values of blood indicators. Materials and Methods: We analyzed 98 patients with pStage II/III GC who underwent postoperative adjuvant S-1 monotherapy. We retrospectively analyzed correlations between 14 parameters obtained from perioperative routine blood tests to assess their influence on the withdrawal of postoperative adjuvant S-1 monotherapy, within 6 months after discontinuation. Results: Postoperative adjuvant chemotherapy was discontinued in 21 patients (21.4%) within 6 months. Univariable analysis revealed that high preoperative albumin-bilirubin (ALBI) scores had the highest odds ratio (OR) for predicting the failure of adjuvant S-1 chemotherapy (OR, 6.47; 95% confidence interval [CI], 2.08-20.1; cutoff value, -2.696). The high ALBI group had a significantly shorter time to failure of postoperative adjuvant S-1monotherapy (hazard ratio, 3.48; 95% CI, 1.69-7.25; P=0.001). Multivariable analysis identified high preoperative ALBI score as an independent prognostic factor for tolerability (OR, 10.3; 95% CI, 2.33-45.8; P=0.002). Conclusions: Preoperative ALBI shows promise as an indicator associated with the tolerability of adjuvant S-1 monotherapy in patients with pStage II/III GC.

Keywords

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  3. Andre T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, et al. Adjuvant treatment of colon cancer MOSAIC study's main results. Bull Cancer 2006;93 Suppl 1:S5-S9.
  4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-444. https://doi.org/10.1016/S0140-6736(11)61625-5
  5. Sandra-Petrescu F, Herrle F, Burkholder I, Kienle P, Hofheinz RD. Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial. BMC Cancer 2018;18:369. https://doi.org/10.1186/s12885-018-4309-6
  6. Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol 2019;4:208-216. https://doi.org/10.1016/S2468-1253(18)30383-2
  7. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer 2013;16:133-139. https://doi.org/10.1007/s10120-012-0158-1
  8. Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol 2013;20:2000-2006. https://doi.org/10.1245/s10434-012-2776-6
  9. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-558.
  10. Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, et al. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 2016;14:24. https://doi.org/10.1186/s12955-016-0426-6
  11. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19. https://doi.org/10.1007/s10120-016-0622-4
  12. Kanda M, Mizuno A, Tanaka C, Kobayashi D, Fujiwara M, Iwata N, et al. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine (Baltimore) 2016;95:e3781. https://doi.org/10.1097/MD.0000000000003781
  13. Kanda M, Tanaka C, Kobayashi D, Uda H, Inaoka K, Tanaka Y, et al. Preoperative albumin-bilirubin grade predicts recurrences after radical gastrectomy in patients with pT2-4 gastric cancer. World J Surg 2018;42:773-781. https://doi.org/10.1007/s00268-017-4234-x
  14. Andreatos N, Amini N, Gani F, Margonis GA, Sasaki K, Thompson VM, et al. Albumin-bilirubin score: predicting short-term outcomes including bile leak and post-hepatectomy liver failure following hepatic resection. J Gastrointest Surg 2017;21:238-248. https://doi.org/10.1007/s11605-016-3246-4
  15. Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Lee YH, et al. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep 2018;8:4773. https://doi.org/10.1038/s41598-018-22923-4
  16. Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 2006;9:145-155. https://doi.org/10.1007/s10120-006-0373-8
  17. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5:226-243. https://doi.org/10.1038/sj.tpj.6500320
  18. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996;14:257-267. https://doi.org/10.1200/JCO.1996.14.1.257
  19. Miura K, Konishi J, Miyake T, Makita M, Hojo A, Masaki Y, et al. A host-dependent prognostic model for elderly patients with diffuse large B-cell lymphoma. Oncologist 2017;22:554-560. https://doi.org/10.1634/theoncologist.2016-0260
  20. Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol 2017;8:314-323. https://doi.org/10.21037/jgo.2016.09.17
  21. Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol 2015;9:1549-1560. https://doi.org/10.1586/17474124.2015.1094373
  22. Kanda M, Murotani K, Kobayashi D, Tanaka C, Yamada S, Fujii T, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery 2015;158:1573-1580. https://doi.org/10.1016/j.surg.2015.05.017
  23. Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, et al. Effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients: a randomized controlled clinical trial. Ann Surg Oncol 2016;23:2928-2935. https://doi.org/10.1245/s10434-016-5221-4

Cited by

  1. Gimeracil/oteracil/tegafur : Leucopenia and dacryorrhaea: 2 case reports vol.1773, pp.1, 2019, https://doi.org/10.1007/s40278-019-68931-x